CN110771890A - Small-molecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and preparation method thereof - Google Patents
Small-molecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and preparation method thereof Download PDFInfo
- Publication number
- CN110771890A CN110771890A CN201911021187.2A CN201911021187A CN110771890A CN 110771890 A CN110771890 A CN 110771890A CN 201911021187 A CN201911021187 A CN 201911021187A CN 110771890 A CN110771890 A CN 110771890A
- Authority
- CN
- China
- Prior art keywords
- enzymolysis
- temperature
- parts
- weight
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 50
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 45
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 230000036039 immunity Effects 0.000 title claims abstract description 28
- 210000005036 nerve Anatomy 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000003384 small molecules Chemical class 0.000 title claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 57
- 239000000843 powder Substances 0.000 claims abstract description 43
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 42
- 239000012138 yeast extract Substances 0.000 claims abstract description 42
- 229940092309 pumpkin seed extract Drugs 0.000 claims abstract description 21
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 12
- 241001107116 Castanospermum australe Species 0.000 claims abstract description 6
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 6
- 240000007049 Juglans regia Species 0.000 claims abstract description 6
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 6
- 241000234435 Lilium Species 0.000 claims abstract description 6
- 229930195725 Mannitol Natural products 0.000 claims abstract description 6
- 244000197580 Poria cocos Species 0.000 claims abstract description 6
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000021279 black bean Nutrition 0.000 claims abstract description 6
- 239000000594 mannitol Substances 0.000 claims abstract description 6
- 235000010355 mannitol Nutrition 0.000 claims abstract description 6
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 6
- 239000011669 selenium Substances 0.000 claims abstract description 6
- 235000020234 walnut Nutrition 0.000 claims abstract description 6
- 241000408747 Lepomis gibbosus Species 0.000 claims description 65
- 235000020236 pumpkin seed Nutrition 0.000 claims description 65
- 238000003756 stirring Methods 0.000 claims description 60
- 241000157835 Gardenia Species 0.000 claims description 57
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 55
- 239000011550 stock solution Substances 0.000 claims description 52
- 239000007788 liquid Substances 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 44
- 238000010438 heat treatment Methods 0.000 claims description 40
- 239000012528 membrane Substances 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 34
- 108010019160 Pancreatin Proteins 0.000 claims description 29
- 229940055695 pancreatin Drugs 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 239000002994 raw material Substances 0.000 claims description 22
- 230000001105 regulatory effect Effects 0.000 claims description 22
- 239000008367 deionised water Substances 0.000 claims description 21
- 229910021641 deionized water Inorganic materials 0.000 claims description 21
- 239000011259 mixed solution Substances 0.000 claims description 20
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 18
- 102000015439 Phospholipases Human genes 0.000 claims description 18
- 108010064785 Phospholipases Proteins 0.000 claims description 18
- 239000004365 Protease Substances 0.000 claims description 18
- 210000002421 cell wall Anatomy 0.000 claims description 18
- 238000001471 micro-filtration Methods 0.000 claims description 18
- 230000001603 reducing effect Effects 0.000 claims description 18
- 108090000526 Papain Proteins 0.000 claims description 17
- 235000019834 papain Nutrition 0.000 claims description 17
- 229940055729 papain Drugs 0.000 claims description 17
- 238000009210 therapy by ultrasound Methods 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000012466 permeate Substances 0.000 claims description 15
- 238000000108 ultra-filtration Methods 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 108010073324 Glutaminase Proteins 0.000 claims description 14
- 102000009127 Glutaminase Human genes 0.000 claims description 14
- 229940088598 enzyme Drugs 0.000 claims description 14
- 230000035699 permeability Effects 0.000 claims description 14
- 239000013049 sediment Substances 0.000 claims description 14
- 210000005253 yeast cell Anatomy 0.000 claims description 13
- 108091005658 Basic proteases Proteins 0.000 claims description 12
- 230000002255 enzymatic effect Effects 0.000 claims description 12
- 239000000413 hydrolysate Substances 0.000 claims description 12
- 235000021251 pulses Nutrition 0.000 claims description 12
- 108091005508 Acid proteases Proteins 0.000 claims description 11
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 11
- 210000000170 cell membrane Anatomy 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 230000001276 controlling effect Effects 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 239000000287 crude extract Substances 0.000 claims description 9
- 230000009849 deactivation Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 102000016943 Muramidase Human genes 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000012588 trypsin Substances 0.000 claims description 8
- 108010059892 Cellulase Proteins 0.000 claims description 7
- 108010059820 Polygalacturonase Proteins 0.000 claims description 7
- 229940106157 cellulase Drugs 0.000 claims description 7
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 101710163270 Nuclease Proteins 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 239000000919 ceramic Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 230000001678 irradiating effect Effects 0.000 claims description 6
- 239000012465 retentate Substances 0.000 claims description 6
- 238000001223 reverse osmosis Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 240000001008 Dimocarpus longan Species 0.000 claims description 5
- 235000000235 Euphoria longan Nutrition 0.000 claims description 5
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 5
- 240000002853 Nelumbo nucifera Species 0.000 claims description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 5
- 240000003768 Solanum lycopersicum Species 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 108060004795 Methyltransferase Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 244000111489 Gardenia augusta Species 0.000 abstract 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- 229960002275 pentobarbital sodium Drugs 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 230000000242 pagocytic effect Effects 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 6
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002390 cell membrane structure Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000004622 sleep time Effects 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229960000796 barbital sodium Drugs 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000003860 sleep quality Effects 0.000 description 4
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 3
- 229940074393 chlorogenic acid Drugs 0.000 description 3
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 3
- 235000001368 chlorogenic acid Nutrition 0.000 description 3
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 230000004620 sleep latency Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101001050208 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Putative ATP-dependent RNA helicase ECM32 Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000033629 detection of yeast Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 flavonoids Chemical class 0.000 description 1
- MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical compound FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/32—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using phonon wave energy, e.g. sound or ultrasonic waves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/25—Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity, a preparation method and a preparation method thereof, wherein the micromolecule polypeptide compound nutrient comprises the following components in parts by weight: 15-20 parts of soybean peptide powder, 10-15 parts of pumpkin seed extract, 5-8 parts of poria cocos, 3-5 parts of selenium-rich cordyceps militaris powder, 2-3 parts of yeast extract, 3-5 parts of spina date seed, 5-8 parts of gardenia fruit oil, 1-2 parts of trehalose, 5-8 parts of lily, 2-3 parts of radix ophiopogonis, 8-10 parts of walnut kernel, 3-5 parts of black bean powder and 5-8 parts of mannitol. The pumpkin seed extract, the yeast extract and the gardenia oil extract are prepared by a special extraction process, so that the active ingredients of the pumpkin seed extract, the yeast extract and the gardenia oil extract are fully released, and the pumpkin seed extract, the yeast extract and the gardenia oil extract are reasonably matched with other components to achieve good effects of enhancing immunity, soothing nerves and helping sleep.
Description
Technical Field
The invention relates to the field of health-care food. More specifically, the invention relates to a micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and a preparation method thereof.
Background
Insomnia refers to the difficulty in ensuring sleep quality during night sleep, difficulty in falling asleep or short sleep time, light dreaminess and easy wakening. Modern medicine considers that the main reason for insomnia is that nerves in the brain are in an overstrained state or a mood fluctuation state for a long time, such as long-time work, high psychological stress, frequent shift, overfatigue and sadness. The long-term insomnia causes patients to have cachexia, nervous disturbance, immunity reduction, hypomnesis and the like, and is more likely to cause the attack of various diseases such as cerebral hemorrhage, hypertension, hemiplegia, diabetes and the like, thereby increasing the death probability of the patients.
To alleviate the imbalance of excitation and inhibition of the cerebral cortex, relaxation therapy and drug therapy are commonly used. The relaxation therapy mainly aims at guiding patients, relaxing mood and enabling the patients to know that insomnia is caused by normal anxiety or emotion and can cure and relieve the anxiety, and the method has good effect on some patients, but has large limitation and varies from person to person. The drug therapy is often combined with relaxation therapy, and tranquilizers are adopted to inhibit the abnormal activity of cerebral nerves, such as fluoroamine, but drug resistance is generated after long-term administration, insomnia is aggravated after drug withdrawal, and the drugs increase the burden of liver and kidney, and the liver and kidney functions need to be checked regularly.
In addition, the low immunity can be seen in people of various ages, such as children, the old, people taking immunosuppressants for a long time after organ transplantation, malignant tumor patients receiving radiotherapy and chemotherapy, people with reduced immunity caused by lack of nutrition, medical workers with high probability of contacting infectious diseases for a long time, middle-aged people under great deep life pressure, and the like, and the low immunity is widely distributed among people. Among them, for middle-aged people with great deep life and workplace pressure, the thinking and brain activity of middle-aged people are frequent after the middle-aged people, so the pressure is increased, the sleep is less and less, the sleep quality is poorer and poorer, the immunity of the organism is too low, the bacteria and virus infection is easily caused, and the middle-aged people easily feel fatigue, the gastrointestinal function is reduced, the self-protection capability is poor, the middle-aged people are easily attacked by infectious diseases, the spirit is low, the mind and the body are pallid, the serious infection is easily caused, and the like.
Disclosure of Invention
In order to solve the technical problems, the invention provides a micromolecule polypeptide compound nutrient for soothing nerves and helping sleep and improving immunity and a preparation method thereof.
To achieve these objects and other advantages in accordance with the present invention, there is provided a small molecule polypeptide complex nutrient for soothing nerves, aiding sleep and improving immunity, comprising: 15-20 parts of oat flour, 10-15 parts of pumpkin seed extract, 3-8 parts of cored lotus seed, 5-8 parts of poria cocos, 3-5 parts of selenium-rich cordyceps militaris powder, 2-3 parts of yeast extract, 8-10 parts of tomato powder, 3-5 parts of honey, 10-15 parts of denucleated dried longan, 5-8 parts of gardenia fruit oil, 5-8 parts of lily, 2-3 parts of radix ophiopogonis, 8-10 parts of walnut kernel, 3-5 parts of black bean powder and 5-8 parts of mannitol.
Preferably, the preparation method of the pumpkin seed extract comprises the following steps:
s11, taking fresh pumpkin seeds, soaking at 25 ℃ for 10-12h, taking out, washing with deionized water for 2-3 times, drying, grinding, and sieving with a 100-mesh sieve to obtain pumpkin seed powder;
s12, adding deionized water with the weight 10-12 times that of the pumpkin seed powder into the pumpkin seed powder to obtain an enzymolysis raw material, and carrying out enzymolysis on the enzymolysis raw material to obtain an enzymolysis system; wherein, the enzymolysis process comprises the following steps:
carrying out first enzymolysis: adjusting the pH value of the enzymolysis raw material to 8.0-9.0, adding trypsin which accounts for 3-4% of the weight of the enzymolysis raw material, fully stirring, heating to 40-45 ℃ while stirring, and preserving heat for 35-40min to obtain a first enzymolysis system;
and (3) carrying out second enzymolysis: after the temperature of the first enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 3.5-4.5, adding pectinase according to 3.5-4.5% of the weight of the first enzymolysis system, fully stirring, heating to 45-50 ℃ while stirring, and preserving heat for 30-35min to obtain a second enzymolysis system;
and (3) carrying out third enzymolysis: after the temperature of the second enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 4.0-5.5, adding cellulase according to 2-4% of the weight of the second enzymolysis system, fully stirring, heating to 50-65 ℃ while stirring, and preserving heat for 25-35min to obtain a third enzymolysis system;
s13, after the enzymolysis is finished, heating the obtained third enzymolysis system to 85 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a pumpkin seed enzymolysis system;
s14, adding phospholipase accounting for 0.01% of the weight of the pumpkin seed enzymolysis system and pancreatin accounting for 0.02% of the weight of the pumpkin seed enzymolysis system, and recording the total volume value of the pumpkin seed enzymolysis system; then carrying out temperature treatment on the pumpkin seed enzymolysis system to obtain a pumpkin seed extraction system;
the temperature treatment process comprises the following steps:
heating to 35-45 ℃, preserving heat for 60-90min, cooling to 30-40 ℃, preserving heat for 25-35min, and recording a first volume value of the reaction system at the moment; adding a first mixed solution containing deionized water, phospholipase and pancreatin according to (total volume-first volume) 65%, wherein the first mixed solution contains 97.5% of deionized water, 1% of phospholipase and 1.5% of pancreatin according to weight ratio; after the first mixed solution is added, heating to 45-50 ℃, preserving heat for 75-85min, then cooling to 40-45 ℃, preserving heat for 30-35min, and recording a second volume value of the reaction system at the moment; adding a second mixed solution containing deionized water, phospholipase and pancreatin according to (total volume-second volume) 45%, wherein the second mixed solution contains 98% of deionized water, 1% of phospholipase and 1% of pancreatin according to weight ratio; adding the second mixed solution, heating to 55-65 deg.C, maintaining the temperature for 80-90min, cooling to 50-60 deg.C, and maintaining the temperature for 40-45 min;
s15, adding activated carbon in the pumpkin seed extraction system according to 4% of the weight of the pumpkin seed extraction system, uniformly stirring, keeping the temperature at 65 ℃ for 65-85min, centrifuging, and removing sediments to obtain a pumpkin seed crude extract; filtering the crude extract of pumpkin seeds by diatomite to obtain a first-grade pumpkin seed clear liquid, wherein the filtering pressure is 0.25-0.35 MPa; adding 3% of active carbon into the first-stage pumpkin seed clear liquid according to the weight, standing for 45-50min, centrifuging, and removing sediments to obtain a second-stage pumpkin seed clear liquid;
s16, filtering the second-level pumpkin seed clear liquid by a microfiltration ceramic membrane with the filtering aperture of 0.2-1.0 mu m, wherein the filtering temperature is 50-60 ℃ to obtain microfiltration membrane permeate;
filtering the microfiltration membrane permeate through a 220kDa roll-type ultrafiltration membrane with the molecular weight cutoff of 120-;
and concentrating the ultrafiltration membrane retentate through a roll-type high-pressure reverse osmosis membrane with the molecular weight cutoff of 200-.
Preferably, in step S14, the temperature treatment is performed on the mixed solution and the ultrasonic treatment is performed at the same time, wherein the ultrasonic power is 200-400W, and the ultrasonic treatment time is 10-15 min.
Preferably, the preparation method of the yeast extract comprises the following steps:
s21, putting active dry yeast into a fermentation tank, wherein the diameter of the fermentation tank is 30-40cm, adding water which is 3-5 times of the weight of the active dry yeast into the fermentation tank, and uniformly stirring to obtain a yeast stock solution;
s22, irradiating the yeast stock solution by adopting a plurality of pulse laser light sources for 20-30min, stirring the yeast stock solution under the conditions of 200-300 r/min while irradiating, and carrying out ultrasonic treatment on the yeast stock solution at the same time, wherein the ultrasonic power is 100KW and the ultrasonic treatment temperature is 30-35 ℃; the diameter of a light spot formed on the liquid surface of the yeast stock solution by each pulse laser is 0.5-1cm, and the laser energy of each pulse laser acting on the yeast stock solution is 50 mJ;
s23, carrying out enzymolysis treatment on the yeast stock solution treated in the step S22; and the enzymolysis treatment process comprises the following steps:
(1) and 1, enzymolysis: raising the temperature of the yeast stock solution treated in the step S22 to 20-25 ℃, then lowering the temperature to-45 ℃ at the speed of 15 ℃/min, maintaining the temperature for 1min after lowering the temperature to-45 ℃, and then raising the temperature of the yeast stock solution to 20-25 ℃ at the speed of 10 ℃/min; heating to 20-25 deg.C, adding 1 wt% of alkaline protease and 1.5 wt% of papain into the yeast stock solution, adjusting pH to 7.0-8.0 and temperature to 50-60 deg.C, and performing hydrolysis reaction for 10-12 hr;
adjusting the temperature of yeast stock solution treated by alkaline protease and papain to 40-55 ℃, adding snailase accounting for 1 percent of the weight of the yeast stock solution treated by the alkaline protease and the papain and pancreatin accounting for 2.0 percent of the weight of the yeast stock solution treated by the alkaline protease and the papain, adjusting the pH to 6.5-7.5, filling ozone, stirring the yeast stock solution under the condition of 200 plus 300 revolutions per minute, and carrying out hydrolysis reaction for 3-4h to obtain first enzymatic hydrolysate;
(2) and (3) enzymolysis: adjusting the temperature of the first enzymolysis liquid to 20-25 ℃, reducing the temperature to-45 ℃ at the speed of 10 ℃/min, maintaining the temperature for 0.5min after reducing the temperature to-45 ℃, and increasing the temperature of the first enzymolysis liquid to 20-25 ℃ at the speed of 10 ℃/min; after the temperature is raised to 20-25 ℃, adding 0.5 percent of acid protease and 1.5 percent of nuclease by weight into the first enzymolysis liquid, adjusting the pH to 4.5-6.0 and the temperature to 45-50 ℃, and reacting for 8-10 h;
adjusting the temperature of the first enzymolysis liquid treated by acid protease and nuclease to 40-55 ℃, adding helicase accounting for 0.5 percent of the weight of the yeast stock solution treated by the acid protease and the papain and pancreatin accounting for 1.0 percent of the weight of the yeast stock solution treated by the acid protease and the papain, adjusting the pH to 6.0-7.5, filling ozone, and stirring the first enzymolysis liquid under the condition of 200-;
(3) and (3) enzymolysis: adjusting the temperature of the second enzymolysis liquid to 20-25 ℃, reducing the temperature to-45 ℃ at the speed of 5 ℃/min, maintaining the temperature for 0.5min after reducing the temperature to-45 ℃, and increasing the temperature of the second enzymolysis liquid to 20-25 ℃ at the speed of 12 ℃/min; after the temperature is raised to 20-25 ℃, adding glutaminase and deaminase which are 0.5 percent and 1.0 percent of the weight of the second enzymolysis liquid into the second enzymolysis liquid, adjusting the pH to 5.5-6.0 and the temperature to 45-50 ℃, and reacting for 3-4 hours;
regulating the temperature of the second enzymatic hydrolysate treated by the glutaminase and the deaminase to 40-55 ℃, adding the snailase accounting for 1 percent of the weight of the second enzymatic hydrolysate treated by the glutaminase and the deaminase and the pancreatin accounting for 1 percent of the weight of the second enzymatic hydrolysate treated by the glutaminase and the deaminase, regulating the pH to 6.5-7.5, filling ozone, and stirring the second enzymatic hydrolysate under the condition of 200-300 revolutions per minute for 2-3 hours to obtain a third enzymatic hydrolysate;
s24, after the enzymolysis is finished, heating the obtained third enzymolysis liquid to 90 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a yeast extract stock solution;
s25, adding activated carbon 3% of the yeast extract stock solution by weight, stirring uniformly, keeping the temperature at 55 ℃ for 60-90min, centrifuging, removing sediments to obtain yeast extract clear solution, and filtering under the pressure of 0.25-0.35 MPa;
s26, filtering the clear yeast extract liquid by a microfiltration ceramic membrane, and controlling the operation temperature to be 55-65 ℃ to obtain microfiltration membrane permeate;
filtering the microfiltration membrane permeate through a roll-type ultrafiltration membrane, and controlling the operation temperature to be 55-65 ℃ to obtain ultrafiltration membrane permeate;
concentrating the ultrafiltration membrane retentate by a roll-type high-pressure reverse osmosis membrane to remove water and partial residual inorganic salt and small molecular impurities, and controlling the operation temperature to be below 40 ℃ to obtain a yeast extract concentrated solution;
s27, drying the yeast extract concentrated solution by a vacuum freeze drying method to obtain the yeast extract.
Preferably, the active dry yeast cell has a protein content of 40-45%, a carbohydrate content of 8-10%, and a water content of 4-5%.
Preferably, the extraction method of the gardenia fruit oil comprises the following steps:
s31, putting fresh gardenia fruits into water, soaking at 25 ℃ for 24-36h, taking out, washing with water for 2-3 times, drying, grinding, and sieving with a 100-mesh sieve to obtain gardenia fruit powder;
s32, taking gardenia fruit powder, adding deionized water with the weight 5-10 times of that of the gardenia fruit powder to obtain an enzymolysis raw material, and carrying out enzymolysis on the enzymolysis raw material; wherein, the enzymolysis process comprises the following steps:
carrying out first enzymolysis: adding trypsin in an amount of 5% of the weight of the gardenia fruit powder and adding a permeability regulating solution for regulating the permeability of cell membranes and/or cell walls in an amount of 45-55% of the weight of the gardenia fruit powder into the enzymolysis raw materials, regulating the pH value to 6.5-7.5, fully stirring, heating to 42-45 ℃ while stirring, and preserving heat for 30-45min to obtain a first enzymolysis system; the permeability regulating liquid consists of acid solution, glycerol, sodium chloride and lysozyme, and the acid solution comprises the following components in percentage by weight: glycerol: sodium chloride: lysozyme is 1: (0.7-1.0): (0.02-0.05): (0.03-0.06);
and (3) carrying out second enzymolysis: after the temperature of the first enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 3.5-4.5, adding pectinase according to 4% of the weight of the first system, fully stirring, heating to 50-60 ℃ while stirring, and preserving heat for 30-35min to obtain a second enzymolysis system;
and (3) carrying out third enzymolysis: after the temperature of the second enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 4.0-5.5, adding cellulase according to 3.5% of the weight of the second enzymolysis system, fully stirring, heating to 50-65 ℃ while stirring, and preserving heat for 25-35min to obtain a third enzymolysis system;
s33, after the enzymolysis process in the step S22 is finished, heating the obtained third enzymolysis system to 85 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a gardenia fruit enzymolysis system;
s34, adding activated carbon in an enzymolysis system of the gardenia fruit according to 3% of the weight of the gardenia fruit, uniformly stirring, keeping the temperature at 65 ℃ for 65-85min, centrifuging, and removing sediments to obtain a crude extract of gardenia fruit oil; filtering the crude gardenia fruit oil extract by diatomite to obtain a gardenia fruit oil extract, wherein the filtering pressure is 0.3-0.4 MPa; adding 3% of active carbon into the gardenia fruit oil extracting solution according to the weight, standing for 45-50min, centrifuging, and removing sediments; standing for 2-3h, and collecting the upper oil layer to obtain the fructus Gardeniae fruit oil.
Also provides a preparation method of the micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity, which comprises the following steps:
s100, weighing the components according to the component dosage in the claim 1, and mixing for 4-6 minutes to obtain a mixture;
s200, feeding the mixture into a granulator for granulation to obtain a coarse finished product, wherein the steam pressure in the granulator is 0.5-0.8Mpa, the granulation temperature is 75-85 ℃, and the diameter of a die hole of the granulator is 1.5-3 mm;
s300, sieving the crude product by using an 8-mesh sieve to finally obtain the micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and the preparation method thereof.
The invention at least comprises the following beneficial effects:
according to the invention, through the extraction process of staged heating, repeated enzymolysis combined with ultrasonic treatment and multiple filtration, the yield and purity of the pumpkin seed extract (containing pumpkin seed protein and the like) and the gardenia oil extract are greatly improved, meanwhile, the yeast autolysis is promoted by adopting a mode of pulse laser, ultrasonic treatment and multiple enzymolysis, so that the yeast cell content is fully released, and further, after the multiple active ingredients are reasonably compounded and used, the formed small molecular polypeptide compound nutrient can remarkably improve the organism immunity of metabolic diseases such as diabetes and the like, crowds with various symptoms such as palpitation, insomnia, uneasiness and the like, and middle-aged people crowds, improve the sleep quality and delay aging.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention.
Detailed Description
The present invention is further described in detail below with reference to examples to enable those skilled in the art to practice the invention with reference to the description.
It will be understood that terms such as "having," "including," and "comprising," as used herein, do not preclude the presence or addition of one or more other elements or groups thereof.
It is to be noted that the test methods described in the following embodiments are conventional methods unless otherwise specified, and the reagents and materials are commercially available without otherwise specified.
< example 1>
The micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity in the embodiment comprises the following components in parts by weight: 15 parts of oat flour, 10 parts of pumpkin seed extract, 3 parts of lotus seed without core, 5 parts of poria cocos, 3 parts of selenium-rich cordyceps militaris powder, 2 parts of yeast extract, 8 parts of tomato powder, 3 parts of honey, 10 parts of dried denucleated longan, 5 parts of gardenia fruit oil, 5 parts of lily, 2 parts of radix ophiopogonis, 8 parts of walnut kernel, 3 parts of black bean powder and 5 parts of mannitol.
Further, the preparation method of the pumpkin seed extract comprises the following steps:
s11, taking fresh pumpkin seeds, soaking at 25 ℃ for 10-12h, taking out, washing with deionized water for 2-3 times, drying, grinding, and sieving with a 100-mesh sieve to obtain pumpkin seed powder;
s12, adding deionized water which is 10-12 times of the weight of the pumpkin seed powder (preferably the pumpkin seed powder) into the pumpkin seed powder to obtain an enzymolysis raw material, and carrying out enzymolysis on the enzymolysis raw material to obtain an enzymolysis system; wherein, the enzymolysis process comprises the following steps:
carrying out first enzymolysis: adjusting the pH value of the enzymolysis raw material to 8.0-9.0 (preferably 8.5), adding trypsin 3-4% (preferably 3.5%) of the enzymolysis raw material, stirring, heating to 40-45 deg.C (preferably 42 deg.C) while stirring, and keeping the temperature for 35-40min to obtain a first enzymolysis system;
and (3) carrying out second enzymolysis: after the temperature of the first enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 3.5-4.5 (preferably 4.0), adding pectinase according to 3.5-4.5% (preferably 4.0%) of the weight of the first enzymolysis system, fully stirring, heating to 45-50 ℃ while stirring, and preserving heat for 30-35min to obtain a second enzymolysis system;
and (3) carrying out third enzymolysis: after the temperature of the second enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 4.0-5.5 (preferably 5.0), adding cellulase according to 2-4% (preferably 3.0%) of the weight of the second enzymolysis system, fully stirring, heating to 50-65 ℃ while stirring, and preserving heat for 25-35min to obtain a third enzymolysis system;
s13, after the enzymolysis is finished, heating the obtained third enzymolysis system to 85 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a pumpkin seed enzymolysis system;
s14, adding 0.01% phospholipase and 0.02% pancreatin into the pumpkin seed enzymolysis system, and recording
The total volume value of the pumpkin seed enzymolysis system; then carrying out temperature treatment on the pumpkin seed enzymolysis system at the moment, and simultaneously carrying out ultrasonic treatment on the pumpkin seed enzymolysis system, wherein the ultrasonic power is 200-400W (preferably 300W), and the ultrasonic treatment time is 10-15min (preferably 12min), so as to obtain a pumpkin seed extraction system;
the temperature treatment process comprises the following steps:
heating to 35-45 deg.C (preferably 40 deg.C), maintaining for 60-90min (preferably 70min), cooling to 30-40 deg.C (preferably 35 deg.C), maintaining for 25-35min (preferably 35min), and recording the first volume value of the reaction system; adding a first mixed solution containing deionized water, phospholipase and pancreatin according to (total volume-first volume) 65%, wherein the first mixed solution contains 97.5% of deionized water, 1% of phospholipase and 1.5% of pancreatin according to weight ratio; adding the first mixed solution, heating to 45-50 deg.C, maintaining the temperature for 75-85min (preferably 80min), cooling to 40-45 deg.C (preferably 42 deg.C), maintaining the temperature for 30-35min, and recording the second volume value of the reaction system; adding a second mixed solution containing deionized water, phospholipase and pancreatin according to (total volume-second volume) 45%, wherein the second mixed solution contains 98% of deionized water, 1% of phospholipase and 1% of pancreatin according to weight ratio; adding the second mixed solution, heating to 55-65 deg.C, maintaining the temperature for 80-90min (preferably 85min), cooling to 50-60 deg.C (preferably 55 deg.C), and maintaining the temperature for 40-45 min; in the step, water, phospholipase and pancreatin in corresponding proportion are supplemented after each temperature rise and heat preservation stage is finished, so that a reaction system after water evaporation and partial enzyme inactivation is compensated, and the reaction system is always in a better enzymolysis environment to achieve the best enzymolysis effect;
s15, adding activated carbon in the pumpkin seed extraction system according to 4% of the weight of the pumpkin seed extraction system, uniformly stirring, keeping the temperature at 65 ℃ for 65-85min (preferably 75min), centrifuging for 5-8min under the conditions of 8000-; filtering the crude extract of pumpkin seeds by diatomite to obtain a first-grade pumpkin seed clear liquid, wherein the filtering pressure is 0.25-0.35MPa (preferably 0.3 MPa); adding 3% of active carbon into the first-stage pumpkin seed clear liquid according to the weight, standing for 45-50min, centrifuging, and removing sediments to obtain a second-stage pumpkin seed clear liquid;
s16, filtering the second-level pumpkin seed clear liquid by a microfiltration ceramic membrane with the filtering aperture of 0.2-1.0 μm, wherein the filtering temperature is 50-60 ℃ (preferably 55 ℃) to obtain microfiltration membrane permeate;
filtering the microfiltration membrane permeate through a 220kDa roll-type ultrafiltration membrane with the molecular weight cut-off of 120-;
concentrating the ultrafiltration membrane retentate through a roll-type high-pressure reverse osmosis membrane with the molecular weight cutoff of 200-;
the cell wall tissues of the pumpkin seed cells are rich, the pectinase and the cellulase can destroy the cell wall structures, the phospholipase can destroy the cell membrane structures, and the trypsin and the pancreatin can decompose proteins, so that the cell wall and the cell membrane structures of the pumpkin seed cells can be fully destroyed by the enzymes in combination with independent enzymolysis and ultrasonic treatment conditions, the content of the pumpkin seed cells is released, macromolecular proteins are further decomposed into micromolecular polypeptides which can be easily absorbed by a human body, and the synthesis of immunoglobulin is promoted through the micromolecular pumpkin seed proteins, so that the humoral immunity is effectively enhanced; the T lymphocyte proliferation can be improved, the cellular immune response can be enhanced, the release of various endocrine hormones can be promoted, the T lymphocyte proliferation comprises insulin, growth hormone, prolactin, antidiuretic hormone, catecholamine and the like, the effect of regulating immunity is achieved, meanwhile, the cell structure (such as cell membranes and the like) composition of the components can be repeatedly impacted and destroyed in different temperature change environments through staged temperature rise and heat preservation, meanwhile, water, pancreatin and phospholipase in corresponding proportions are supplemented after each temperature rise and heat preservation stage is finished, so that the reaction system after water evaporation and enzyme inactivation is compensated, and the reaction system is always in a better enzymolysis environment, and the optimal enzymolysis effect can be achieved.
Further, yeast extract (yeast extract) is a substance which is rich in natural active ingredients such as small molecular amino acids, peptides, nucleotides, vitamins and the like and is formed by extracting proteins, nucleic acids, vitamins and the like in yeast after wall breaking and carrying out biological enzymolysis. Wherein, the amino acid is the main component of the natural moisturizing factor in the skin cuticle, is easy to be absorbed by the skin, restores the elasticity of the aged epidermis and delays the skin aging; nucleic acid and nucleotide are main genetic materials of human body, and have the functions of promoting metabolism, increasing protein synthesis speed, etc., so as to enhance immune function and SOD activity and improve anti-aging capability. To this end, the present embodiment also provides a method for preparing a yeast extract, which comprises:
s21, putting active dry yeast into a fermentation tank, wherein the diameter of the fermentation tank is 30-40cm (preferably 35cm), adding water which is 3-5 times (preferably 4 times) the weight of the active dry yeast into the fermentation tank, and uniformly stirring to obtain a yeast stock solution; the active dry yeast cell has the protein content of 40-45%, the carbohydrate content of 8-10% and the water content of 4-5%;
s22, irradiating the yeast stock solution by adopting a plurality of (preferably 8-10) pulse laser light sources for 20-30min (preferably 25cm), stirring the yeast stock solution under the conditions of 200-300 r/min while irradiating, and simultaneously carrying out ultrasonic treatment on the yeast stock solution, wherein the ultrasonic power is 100KW, and the ultrasonic treatment temperature is 30-35 ℃ (preferably 32 ℃); the diameter of a light spot formed on the liquid surface of the yeast stock solution by each pulse laser is 0.5-1cm, and the laser energy of each pulse laser acting on the yeast stock solution is 50 mJ;
the pulse laser and the ultrasonic wave can generate vacuoles in liquid, near cell membranes/cell walls and in cell sap, high temperature and high pressure (5000K, 50Mpa) are generated at the moment of collapsing the vacuoles, so that the cell walls and the plasma membranes of the surrounding yeast cells are broken down or the permeability of the plasma membranes is changed, and the contents of the yeast cells are separated out;
s23, carrying out enzymolysis treatment on the yeast stock solution treated in the step S22; and the enzymolysis treatment process comprises the following steps:
(1) and 1, enzymolysis: raising the temperature of the yeast stock solution treated in the step S22 to 20-25 ℃, then lowering the temperature to-45 ℃ at the speed of 15 ℃/min, maintaining the temperature for 1min after lowering the temperature to-45 ℃, and then raising the temperature of the yeast stock solution to 20-25 ℃ at the speed of 10 ℃/min; heating to 20-25 deg.C, adding alkaline protease and papain 1.5% of the yeast stock solution, adjusting pH to 7.0-8.0 (preferably 7.5) and temperature to 50-60 deg.C (preferably 55 deg.C), and performing hydrolysis reaction for 10-12h (preferably 10.5 h);
adjusting the temperature of yeast stock solution treated by alkaline protease and papain to 40-55 ℃ (preferably 45 ℃), adding helicase 1 wt% and pancreatin 2.0 wt% of the yeast stock solution treated by alkaline protease and papain, adjusting the pH to 6.5-7.5 (preferably 7.0), introducing ozone, stirring the yeast stock solution under the conditions of 200-300 r/min, and performing hydrolysis reaction for 3-4h (preferably 3.5h) to obtain a first enzymolysis solution;
(4) and (3) enzymolysis: adjusting the temperature of the first enzymolysis liquid to 20-25 ℃, reducing the temperature to-45 ℃ at the speed of 10 ℃/min, maintaining the temperature for 0.5min after reducing the temperature to-45 ℃, and increasing the temperature of the first enzymolysis liquid to 20-25 ℃ at the speed of 10 ℃/min; after the temperature is raised to 20-25 ℃, adding 0.5 percent of acid protease and 1.5 percent of nuclease by weight into the first enzymolysis liquid, adjusting the pH to 4.5-6.0 (preferably 5.5) and the temperature to 45-50 ℃ (preferably 48 ℃), and reacting for 8-10h (preferably 9 h);
adjusting the temperature of the first enzymolysis solution treated by acid protease and nuclease to 40-55 ℃ (preferably 42 ℃), adding helicase accounting for 0.5% of the weight of the yeast stock solution treated by the acid protease and the papain and pancreatin accounting for 1.0%, adjusting the pH to 6.0-7.5 (preferably 7.0), filling ozone, and stirring the first enzymolysis solution under the conditions of 200-;
(5) and (3) enzymolysis: adjusting the temperature of the second enzymolysis liquid to 20-25 ℃, reducing the temperature to-45 ℃ at the speed of 5 ℃/min, maintaining the temperature for 0.5min after reducing the temperature to-45 ℃, and increasing the temperature of the second enzymolysis liquid to 20-25 ℃ at the speed of 12 ℃/min; after the temperature is raised to 20-25 ℃, adding glutaminase and deaminase which are 0.5 percent and 1.0 percent of the weight of the glutaminase and deaminase into the second enzymolysis liquid, adjusting the pH to 5.5-6.0 (preferably 5.8) and the temperature to 45-50 ℃ (preferably 42 ℃), and reacting for 3-4h (preferably 3.5 h);
regulating the temperature of the second enzymolysis solution treated by the glutaminase and the deaminase to 40-55 ℃ (preferably 42 ℃), adding the snailase accounting for 1 percent of the weight of the second enzymolysis solution treated by the glutaminase and the deaminase and the pancreatin accounting for 1 percent of the weight of the second enzymolysis solution treated by the glutaminase and the deaminase, regulating the pH to 6.5-7.5, filling ozone, and stirring the second enzymolysis solution according to the condition of 200-300 r/min for hydrolysis for 2-3h to obtain a third enzymolysis solution;
in the step, through the stepwise sudden temperature rise and the sudden temperature drop, ice crystals are generated in the yeast cells, so that the cell structures of the yeast cells are damaged through the expansion and piercing of the ice crystals, and meanwhile, the alkaline protease, the papain, the acidic protease, the helicase, the pancreatin, the glutaminase and the deaminase can all decompose protein, so that the cell membrane structure can be further damaged, macromolecular protein released in the yeast cells is hydrolyzed into micromolecular amino acid, the activity of the micromolecular amino acid is enhanced, and the effects of resisting aging, improving the immunity and the like are fully exerted; in addition, ozone can destroy the cell membrane structure through oxidation, further promote the destruction of the yeast cell structure and promote the release of the content thereof;
s24, after the enzymolysis is finished, heating the obtained third enzymolysis liquid to 90 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a yeast extract stock solution;
s25, adding activated carbon 3% of the yeast extract stock solution by weight, stirring uniformly, keeping the temperature at 55 ℃ for 60-90min, centrifuging, removing sediments to obtain yeast extract clear solution, and filtering under the pressure of 0.25-0.35 MPa;
s26, filtering the clear yeast extract liquid by a microfiltration ceramic membrane, and controlling the operation temperature to be 55-65 ℃ to obtain microfiltration membrane permeate;
filtering the microfiltration membrane permeate through a roll-type ultrafiltration membrane, and controlling the operation temperature to be 55-65 ℃ to obtain ultrafiltration membrane permeate;
concentrating the ultrafiltration membrane retentate by a roll-type high-pressure reverse osmosis membrane to remove water and partial residual inorganic salt and small molecular impurities, and controlling the operation temperature to be below 40 ℃ to obtain a yeast extract concentrated solution;
s27, drying the yeast extract concentrated solution by a vacuum freeze drying method to obtain the yeast extract.
In addition, the gardenia fruits are rich in resources, low in price and easy to obtain, have multiple effects and play more and more important roles in modern food industry, and particularly mainly contain compounds such as flavonoids, iridoid mushrooms and cycloenoximones, and components such as crocin, pectin, tannin, polysaccharide, crocin acid, volatile oil, wherein the flavonoids have an auxiliary treatment effect on diseases such as hypertension, and can realize the effects of reducing blood pressure, blood sugar and the like. Therefore, the present embodiment also provides a method for extracting gardenia fruit oil, which comprises:
s31, putting fresh gardenia fruits into water, soaking at 25 ℃ for 24-36h, taking out, washing with water for 2-3 times, drying, grinding, and sieving with a 100-mesh sieve to obtain gardenia fruit powder;
s32, taking gardenia fruit powder, adding deionized water with the weight 5-10 times (preferably 8 times) of that of the gardenia fruit powder to obtain an enzymolysis raw material, and carrying out enzymolysis on the enzymolysis raw material; wherein, the enzymolysis process comprises the following steps:
carrying out first enzymolysis: adding trypsin in an amount of 5% of the weight of the gardenia fruit powder and adding a permeability regulating solution for regulating the permeability of cell membranes and/or cell walls in an amount of 45-55% (preferably 50%) of the weight of the gardenia fruit powder into the enzymolysis raw material, regulating the pH value to 6.5-7.5 (preferably 7.0), fully stirring, raising the temperature to 42-45 ℃ (preferably 43.5 ℃) while stirring, and preserving the temperature for 30-45min (preferably 35min) to obtain a first enzymolysis system; the permeability regulating liquid consists of acid solution, glycerol, sodium chloride and lysozyme, and the acid solution comprises the following components in percentage by weight: glycerol: sodium chloride: lysozyme is 1: (0.7-1.0): (0.02-0.05): (0.03-0.06) (preferably an acid solution: glycerin: sodium chloride: lysozyme: 1: 0.8: 0.03: 0.04, and the acid solution is a citric acid solution);
and (3) carrying out second enzymolysis: after the temperature of the first enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 3.5-4.5 (preferably 4.0), adding pectinase according to 4% of the weight of the first system, fully stirring, heating to 50-60 ℃ (preferably 55 ℃) while stirring, and keeping the temperature for 30-35min (preferably 32min) to obtain a second enzymolysis system;
and (3) carrying out third enzymolysis: after the temperature of the second enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 4.0-5.5 (preferably 5.0), adding cellulase according to 3.5% of the weight of the second enzymolysis system, fully stirring, heating to 50-65 ℃ (preferably 60 ℃) while stirring, and preserving heat for 25-35min (preferably 30min) to obtain a third enzymolysis system;
s33, after the enzymolysis process in the step S22 is finished, heating the obtained third enzymolysis system to 85 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a gardenia fruit enzymolysis system;
s34, adding activated carbon in an enzymolysis system of the gardenia fruit according to 3% of the weight of the gardenia fruit, uniformly stirring, carrying out heat preservation at 65 ℃ for 65-85min (preferably 75min), centrifuging, and removing sediments to obtain a crude extract of gardenia fruit oil; filtering the crude extract with diatomaceous earth to obtain fructus Gardeniae extract at 0.3-0.4MPa (preferably 0.35 MPa); adding 3% of active carbon into the gardenia fruit oil extracting solution according to the weight, standing for 45-50min, centrifuging, and removing sediments; standing for 2-3h (preferably 2.5h), and collecting the upper oil layer to obtain the fructus Gardeniae fruit oil.
< example 2>
The difference between the embodiment and the embodiment 1 is that the small molecular polypeptide compound nutrient for soothing the nerves, helping sleep and improving immunity consists of the following components in parts by weight: 20 parts of oat flour, 15 parts of pumpkin seed extract, 8 parts of lotus seed without core, 8 parts of poria cocos, 5 parts of selenium-rich cordyceps militaris powder, 3 parts of yeast extract, 10 parts of tomato powder, 5 parts of honey, 15 parts of dried denucleated longan, 8 parts of gardenia fruit oil, 8 parts of lily, 3 parts of radix ophiopogonis, 10 parts of walnut kernel, 5 parts of black bean powder and 8 parts of mannitol.
< example 3>
The difference between the embodiment and the embodiment 1 is that the small molecular polypeptide compound nutrient for soothing the nerves, helping sleep and improving immunity consists of the following components in parts by weight: 18 parts of oat flour, 12 parts of pumpkin seed extract, 6 parts of lotus seed without core, 7 parts of poria cocos, 4 parts of selenium-rich cordyceps militaris powder, 2.5 parts of yeast extract, 9 parts of tomato powder, 4 parts of honey, 12 parts of dried longan without core, 7 parts of gardenia fruit oil, 6 parts of lily, 2.5 parts of radix ophiopogonis, 9 parts of walnut kernel, 4 parts of black bean powder and 7 parts of mannitol.
< detection result of pumpkin seed extract >
Pumpkin seed protein was extracted by the method described in example 1 of the patent application No. 201810995144.3 ("a method for preparing pumpkin seed protein") as comparative example 1, and it was subjected to determination of free amino acid content by formaldehyde titration method and determination of total nitrogen content according to the micro kjeldahl method with the pumpkin seed extract obtained by the method for preparing pumpkin seed extract in examples 1-3 of the present invention, and the degree of hydrolysis was calculated from the Degree of Hydrolysis (DH) ═ free amino acid/total nitrogen × 100%, the results of which are shown in table 1; and detecting the molecular weight and the distribution range of the pumpkin seed protein by high performance gel filtration chromatography, wherein the results are shown in table 2.
TABLE 1 determination of the degree of hydrolysis of pumpkin seed extracts
Comparative example 1 | Example 1 | Example 2 | Example 3 | |
Degree of Hydrolysis (DH) (%) | 19.74 | 10.47 | 9.45 | 9.58 |
TABLE 2 pumpkin seed protein molecular weight and distribution
As can be seen from tables 1-2, in the preparation method of the pumpkin seed extract, macromolecular proteins can be decomposed into small molecular polypeptides by trypsin, pancreatin and the like, wherein the content of free amino acids in the extract prepared by the invention is low (only half of that in comparative example 1), but meanwhile, in the pumpkin seed extract prepared by the invention, the average molecular weight of protein peptides is 800Da, 90% of polypeptides below 1000Da and 75% of polypeptides below 500Da, so that the pumpkin seed extract can be rapidly and efficiently absorbed by human bodies, and the effects of the pumpkin seed extract can be fully exerted.
< results of detection of Yeast extract >
The yeast extract prepared by the method described in example 1 of the patent application No. 201510416294.0 ("a yeast extract and a method for preparing the same") was used as comparative example 2, and the wall-breaking rate, and the protein content, the amino acid content, the solid content, the reducing sugar content, and the nucleotide content of the contents were measured with the yeast extract prepared by the method for preparing a yeast extract according to examples 1 to 3 of the present invention, and the above-mentioned measurements were performed in the prior art, and are not repeated herein, and the measurement results are shown in table 3.
TABLE 3 Yeast extract index determination
Protein content (%) | Amino acid content (%) | Solid content (%) | Reducing sugar content (%) | Nucleotide content (%) | Wall breaking ratio (%) | |
Comparative example 2 | 7.58±1.21 | 20.12±1.21 | 42.43±0.72 | 10.15±0.68 | 5.79±0.21 | 36.31±1.21 |
Example 1 | 10.21±0.84 | 31.33±1.32 | 67.52±0.58 | 15.23±0.58 | 7.11±0.31 | 67.24±1.20 |
Example 2 | 11.44±0.34 | 29.41±0.98 | 68.71±0.74 | 16.14±0.79 | 6.78±0.78 | 71.34±1.58 |
Example 3 | 10.54±0.21 | 32.14±1.24 | 70.02±1.31 | 15.98±1.06 | 7.34±0.11 | 69.55±2.12 |
As can be seen from table 3, in the yeast extract method of the present invention, through reasonable use of cavitation effect generated by pulsed laser and ultrasonic wave, mechanical force applied by ice crystal generated by temperature shock, ozone, various enzymes, and enzymolysis conditions, cell wall/cell membrane structure of yeast cells can be sufficiently destroyed, wall breaking rate can be substantially increased, yeast cells can be sufficiently autolyzed, and content substances, such as protein content, amino acid content, solid content, reducing sugar content, and nucleotide content, can be sufficiently released, specifically, compared with comparative example 2, wall breaking rate in the present invention is increased by about 67%, protein content, amino acid content, solid content, reducing sugar content, and nucleotide content are increased by about 30%, 50%, 62%, 50%, and 22%, and further, respective effects thereof are sufficiently volatilized.
< detection result of Gardenia fruit oil >
The gardenia fruit oil extracted by the method described in example 1 of the patent application with application number 201110321487.X ("method for extracting gardenia oil by aqueous enzymatic method") was used as a comparative example 4, and the content of several main blood sugar and blood lipid lowering active ingredients, i.e., crocin, chlorogenic acid, flavone and gardenoside, was obtained by detecting the gardenia fruit oil obtained by the method for extracting gardenia fruit oil in examples 1 to 3 of the present invention, and the results are shown in table 4.
TABLE 4 Gardenia oil crocin, chlorogenic acid, flavone and geniposide content
Crocin (mg/g) | Flavone (mg/g) | Chlorogenic acid (mg/g) | Geniposide (mg/g) | |
Comparative example 2 | 1.24±0.31 | 3.51±0.25 | 3.14±0.25 | 3.42±0.37 |
Example 1 | 2.24±0.41 | 6.58±0.44 | 4.15±0.58 | 3.92±0.21 |
Example 2 | 2.39±0.29 | 7.25±0.38 | 4.21±0.13 | 3.82±0.35 |
Example 3 | 2.18±0.11 | 6.95±0.57 | 4.23±0.34 | 4.12±0.50 |
Similarly, the cell walls of the gardenia fruits are subjected to full enzymolysis by adopting different enzymes and enzymolysis conditions at different stages, so that cellulose, pectin and other components in the cell walls are completely destroyed, and meanwhile, the acid solution, the glycerol, the sodium chloride and the lysozyme can change the permeability of the cell walls or the cell membrane by changing the cell walls or the cell membrane structure, so that the cell walls and/or the cell wall permeability are regulated by adopting a permeability regulating solution for regulating the permeability of the cell membranes and/or the cell wall, the cell walls and/or the cell wall structure can be destroyed, effective components (such as crocin, flavonoids and the like) in the content of the gardenia fruits are fully released, the blood sugar reducing effect of the gardenia fruits is further exerted, and the small molecular polypeptide compound nutrient is suitable for people with diabetes.
< example 4>
This example also provides a method for preparing the small molecule polypeptide compound nutrient for soothing nerves, aiding sleep and improving immunity of any one of examples 1 to 3, comprising:
s100, weighing the raw material components according to the component dosage in one of the embodiments 1-3, and mixing for 4-6 minutes to obtain a mixture;
s200, feeding the mixture into a granulator for granulation to obtain a crude finished product, wherein the steam pressure in the granulator is 0.5-0.8Mpa (preferably 0.6Mpa), the granulation temperature is 75-85 ℃ (preferably 80 ℃), and the diameter of a die hole of the granulator is 1.5-3mm (preferably 2.0 mm);
s300, sieving the crude product by using an 8-mesh sieve to finally obtain the micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity.
< evaluation test of Immunity-improving Effect >
Female mice of 1 month old were selected for the experiment and divided into 4 groups by weight. The human body recommended dose of the small molecular polypeptide compound nutrient (hereinafter referred to as polypeptide compound nutrient) for soothing the nerves, helping sleep and improving immunity is a shaped product with 0.4 kg/d.kg of body weight, and the equivalent dose of a mouse is 10 times of the human body recommended dose. The human body recommended dose is 5 times, 10 times and 30 times respectively as low, medium and high dose groups. The gavage method is adopted, the gavage is performed once a day, and the control group is filled with distilled water. After each group of mice was continuously administered with the polypeptide complex nutrient for 30 days, the proliferation ability of lymphocytes, the difference in toe swelling, the phagocytic rate of phagocytic cells, and the phagocytic index were measured, and the results are shown in table 5.
TABLE 5 Effect of polypeptide micronutrient complexes on mouse lymphocyte proliferation potency, toe swelling differential, phagocytic rate and phagocytic index
As shown in table 5, after the mice are orally administered with different dosages of the polypeptide complex nutrient for 30 days, compared with the blank control group, the low dose group, the medium dose group and the high dose group have obvious differences in lymphocyte proliferation capacity, toe swelling difference, phagocytic rate and phagocytic index of phagocytic cells, especially the high dose group, the differences are obvious (p is less than 0.05), which indicates that the polypeptide complex nutrient of the present invention can enhance the body immunity by improving the lymph transformation capacity and phagocytic function of phagocytic cells of the mice.
< evaluation test of sleep improvement efficacy >
Male mice of 1 month of age are selected, the weight is 18-22g, the mice are randomly divided into 4 groups according to the weight, and the weights between the groups have no significant difference through t test (p is more than 0.05). According to the polypeptide compound nutrient, the human recommended dose is 0.4 kg/d.kg, and the equivalent dose of the mouse is 10 times of the human recommended dose. 2 times, 5 times and 10 times of the recommended dose of the human body are respectively used as low, medium and high dose. The following tests were carried out by gavage and distilled water injection in the control group, respectively:
(1) test for prolonging sleep time of mice induced by pentobarbital sodium: after the animals continuously give the polypeptide compound nutrient for 26 days, 30mg/kg of sodium pentobarbital is injected into the abdominal cavity of each group of animals, and the injection amount is 0.1ml/10 g. And (3) observing whether the polypeptide compound nutrient can prolong the sleep time induced by the pentobarbital sodium by taking the disappearance of the righting reflex of the mouse as a sleep index. The test was performed at night.
(2) Subthreshold dose sodium pentobarbital sleep incidence test: after the animals continuously give the polypeptide compound nutrient for 26 days, 26mg/kg of sodium pentobarbital is injected into the abdominal cavity of each group of animals, and the injection amount is 0.1ml/10 g. And (3) observing whether the polypeptide compound nutrient can prolong the sleep time induced by the pentobarbital sodium by taking the disappearance of the righting reflex of the mouse as a sleep index. The test was performed at night.
(3) Barbiturate sodium sleep latency test: after the animals continuously give the polypeptide compound nutrient for 26 days, 240mg/kg of barbital sodium is injected into the abdominal cavity of each animal group, and the injection amount is 0.1ml/10 g. And (3) observing whether the polypeptide compound nutrient can prolong the sleep time induced by the pentobarbital sodium by taking the disappearance of the righting reflex of the mouse as a sleep index.
After the test, the indexes were measured, and specific results are shown in table 6.
TABLE 6 Effect of polypeptide Complex Nutrients on sleep in Normal mice
As can be seen from Table 6, after the mice are orally administered with different doses of the polypeptide compound nutrient for 26 days, compared with the control group, the sleep time induced by the low, medium and high dose of the pentobarbital sodium is remarkably improved (p is less than 0.01), which indicates that the polypeptide compound nutrient and the threshold dose of the pentobarbital sodium have synergistic sleep effect; the incidence rate of sleep induced by the low, medium and high dose of the mice in the sub-threshold dose of the pentobarbital sodium is remarkably improved, which shows that the incidence rate of sleep induced by the sub-threshold dose of the pentobarbital sodium in the polypeptide compound nutrient can be increased; meanwhile, the sleep latency of the mice induced by the barbital sodium in the low, medium and high dose groups is obviously shortened, which shows that the polypeptide compound nutrient can prolong the sleep latency of the barbital sodium induced by the barbital sodium.
< test for evaluating anti-aging Effect >
Healthy weaning male and female rats with the weight of 80 +/-20 g are selected, the rats are randomly divided into 4 groups according to the weight, 6 rats in each group of male and female rats are fed with the polypeptide compound nutrients in the embodiments 1-3 of the invention according to 0.5g/kg respectively in the morning and evening after the blank control group feeds the normal diet. After 28 days of feeding, abdominal blood was collected (fasting without water prohibition the day before blood sampling), blood was centrifuged, and serum was taken for measurement of Malondialdehyde (MDA) and vitamin E, and the results are shown in table 7.
Determination of MDA and vitamin E: the MDA was measured for 535nm wavelength by spectrophotometry. Vitamin E was measured by fluorescence spectrophotometry at an excitation wavelength of 295nm and an emission wavelength of 325nm, and the whole operation was carried out in a dark room.
TABLE 7 serum MDA and vitamin E contents of rats raised for 4 weeks
Number of rats (only) | MDA content (mol/ml) | Vitamin E content (mg/dl) | |
Blank control group | 12 | 5.13±1.05 | 1.28±0.16 |
Example 1 | 12 | 2.63±1.28 | 1.74±0.32 |
Example 2 | 12 | 2.47±1.14 | 1.82±0.48 |
Example 3 | 12 | 2.33±0.96 | 1.93±0.12 |
Vitamin E is localized in cells, especially on cell membranes, and can directly act with free radicals generated in cells, thereby blocking the lipid peroxidation process initiated by the free radicals. MDA is one of the lipid peroxidation products, and its level can reflect the lipid peroxidation condition. As can be seen from table 7, after the polypeptide complex nutrient of the present invention is administered, the MDA content of the mice is significantly reduced and the vitamin E content is significantly increased compared to the blank control group, thereby indicating that the polypeptide complex nutrient of the present invention contributes to the peroxidation of less cell membranes, and further has the effect of delaying aging.
It should be noted that the technical features of the above embodiments 1 to 3 can be arbitrarily combined, and the technical solutions obtained by combining the technical features belong to the scope of the present invention.
In conclusion, the invention greatly improves the yield and purity of the pumpkin seed extract (containing pumpkin seed protein and the like) and the gardenia oil extract by the extraction process of staged heating, repeated enzymolysis combined with ultrasonic treatment and multiple filtration, simultaneously promotes yeast autolysis by adopting a mode of pulse laser, ultrasonic treatment and multiple enzymolysis, fully releases yeast cell contents, and further, after multiple active ingredients are reasonably compounded and used, the formed small molecular polypeptide compound nutrient can remarkably enhance the body immunity of metabolic disease people such as diabetes and the like, people with various symptoms such as palpitation, insomnia, uneasiness and the like and middle-aged people, improves the sleep quality of the people, calms the heart and tranquilizes the mind and simultaneously delays aging.
The number of apparatuses and the scale of the process described herein are intended to simplify the description of the present invention. Applications, modifications and variations of the present invention will be apparent to those skilled in the art.
While embodiments of the invention have been described above, it is not limited to the applications set forth in the description and the embodiments, which are fully applicable to various fields of endeavor for which the invention may be embodied with additional modifications as would be readily apparent to those skilled in the art, and the invention is therefore not limited to the details given herein and to the examples shown and described without departing from the generic concept as defined by the claims and their equivalents.
Claims (7)
1. The micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity is characterized by comprising the following components in parts by weight: 15-20 parts of oat flour, 10-15 parts of pumpkin seed extract, 3-8 parts of cored lotus seed, 5-8 parts of poria cocos, 3-5 parts of selenium-rich cordyceps militaris powder, 2-3 parts of yeast extract, 8-10 parts of tomato powder, 3-5 parts of honey, 10-15 parts of denucleated dried longan, 5-8 parts of gardenia fruit oil, 5-8 parts of lily, 2-3 parts of radix ophiopogonis, 8-10 parts of walnut kernel, 3-5 parts of black bean powder and 5-8 parts of mannitol.
2. The small molecule polypeptide complex nutrient of claim 1, wherein the preparation method of the pumpkin seed extract comprises the following steps:
s11, taking fresh pumpkin seeds, soaking at 25 ℃ for 10-12h, taking out, washing with deionized water for 2-3 times, drying, grinding, and sieving with a 100-mesh sieve to obtain pumpkin seed powder;
s12, adding deionized water with the weight 10-12 times that of the pumpkin seed powder into the pumpkin seed powder to obtain an enzymolysis raw material, and carrying out enzymolysis on the enzymolysis raw material to obtain an enzymolysis system; wherein, the enzymolysis process comprises the following steps:
carrying out first enzymolysis: adjusting the pH value of the enzymolysis raw material to 8.0-9.0, adding trypsin which accounts for 3-4% of the weight of the enzymolysis raw material, fully stirring, heating to 40-45 ℃ while stirring, and preserving heat for 35-40min to obtain a first enzymolysis system;
and (3) carrying out second enzymolysis: after the temperature of the first enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 3.5-4.5, adding pectinase according to 3.5-4.5% of the weight of the first enzymolysis system, fully stirring, heating to 45-50 ℃ while stirring, and preserving heat for 30-35min to obtain a second enzymolysis system;
and (3) carrying out third enzymolysis: after the temperature of the second enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 4.0-5.5, adding cellulase according to 2-4% of the weight of the second enzymolysis system, fully stirring, heating to 50-65 ℃ while stirring, and preserving heat for 25-35min to obtain a third enzymolysis system;
s13, after the enzymolysis is finished, heating the obtained third enzymolysis system to 85 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a pumpkin seed enzymolysis system;
s14, adding phospholipase accounting for 0.01% of the weight of the pumpkin seed enzymolysis system and pancreatin accounting for 0.02% of the weight of the pumpkin seed enzymolysis system, and recording the total volume value of the pumpkin seed enzymolysis system; then carrying out temperature treatment on the pumpkin seed enzymolysis system to obtain a pumpkin seed extraction system;
the temperature treatment process comprises the following steps:
heating to 35-45 ℃, preserving heat for 60-90min, cooling to 30-40 ℃, preserving heat for 25-35min, and recording a first volume value of the reaction system at the moment; adding a first mixed solution containing deionized water, phospholipase and pancreatin according to (total volume-first volume) 65%, wherein the first mixed solution contains 97.5% of deionized water, 1% of phospholipase and 1.5% of pancreatin according to weight ratio; after the first mixed solution is added, heating to 45-50 ℃, preserving heat for 75-85min, then cooling to 40-45 ℃, preserving heat for 30-35min, and recording a second volume value of the reaction system at the moment; adding a second mixed solution containing deionized water, phospholipase and pancreatin according to (total volume-second volume) 45%, wherein the second mixed solution contains 98% of deionized water, 1% of phospholipase and 1% of pancreatin according to weight ratio; adding the second mixed solution, heating to 55-65 deg.C, maintaining the temperature for 80-90min, cooling to 50-60 deg.C, and maintaining the temperature for 40-45 min;
s15, adding activated carbon in the pumpkin seed extraction system according to 4% of the weight of the pumpkin seed extraction system, uniformly stirring, keeping the temperature at 65 ℃ for 65-85min, centrifuging, and removing sediments to obtain a pumpkin seed crude extract; filtering the crude extract of pumpkin seeds by diatomite to obtain a first-grade pumpkin seed clear liquid, wherein the filtering pressure is 0.25-0.35 MPa; adding 3% of active carbon into the first-stage pumpkin seed clear liquid according to the weight, standing for 45-50min, centrifuging, and removing sediments to obtain a second-stage pumpkin seed clear liquid;
s16, filtering the second-level pumpkin seed clear liquid by a microfiltration ceramic membrane with the filtering aperture of 0.2-1.0 mu m, wherein the filtering temperature is 50-60 ℃ to obtain microfiltration membrane permeate;
filtering the microfiltration membrane permeate through a 220kDa roll-type ultrafiltration membrane with the molecular weight cutoff of 120-;
and concentrating the ultrafiltration membrane retentate through a roll-type high-pressure reverse osmosis membrane with the molecular weight cutoff of 200-.
3. The small molecule polypeptide composite nutrient of claim 2, wherein in step S14, the temperature treatment and the ultrasonic treatment are performed on the mixed solution, the ultrasonic power is 200-400W, and the ultrasonic treatment time is 10-15 min.
4. The small molecule polypeptide compound nutrient as claimed in claim 1, wherein the preparation method of the yeast extract comprises:
s21, putting active dry yeast into a fermentation tank, wherein the diameter of the fermentation tank is 30-40cm, adding water which is 3-5 times of the weight of the active dry yeast into the fermentation tank, and uniformly stirring to obtain a yeast stock solution;
s22, irradiating the yeast stock solution by adopting a plurality of pulse laser light sources for 20-30min, stirring the yeast stock solution under the conditions of 200-300 r/min while irradiating, and carrying out ultrasonic treatment on the yeast stock solution at the same time, wherein the ultrasonic power is 100KW and the ultrasonic treatment temperature is 30-35 ℃; the diameter of a light spot formed on the liquid surface of the yeast stock solution by each pulse laser is 0.5-1cm, and the laser energy of each pulse laser acting on the yeast stock solution is 50 mJ;
s23, carrying out enzymolysis treatment on the yeast stock solution treated in the step S22; and the enzymolysis treatment process comprises the following steps:
(1) and 1, enzymolysis: raising the temperature of the yeast stock solution treated in the step S22 to 20-25 ℃, then lowering the temperature to-45 ℃ at the speed of 15 ℃/min, maintaining the temperature for 1min after lowering the temperature to-45 ℃, and then raising the temperature of the yeast stock solution to 20-25 ℃ at the speed of 10 ℃/min; heating to 20-25 deg.C, adding 1 wt% of alkaline protease and 1.5 wt% of papain into the yeast stock solution, adjusting pH to 7.0-8.0 and temperature to 50-60 deg.C, and performing hydrolysis reaction for 10-12 hr;
adjusting the temperature of yeast stock solution treated by alkaline protease and papain to 40-55 ℃, adding snailase accounting for 1 percent of the weight of the yeast stock solution treated by the alkaline protease and the papain and pancreatin accounting for 2.0 percent of the weight of the yeast stock solution treated by the alkaline protease and the papain, adjusting the pH to 6.5-7.5, filling ozone, stirring the yeast stock solution under the condition of 200 plus 300 revolutions per minute, and carrying out hydrolysis reaction for 3-4h to obtain first enzymatic hydrolysate;
(2) and (3) enzymolysis: adjusting the temperature of the first enzymolysis liquid to 20-25 ℃, reducing the temperature to-45 ℃ at the speed of 10 ℃/min, maintaining the temperature for 0.5min after reducing the temperature to-45 ℃, and increasing the temperature of the first enzymolysis liquid to 20-25 ℃ at the speed of 10 ℃/min; after the temperature is raised to 20-25 ℃, adding 0.5 percent of acid protease and 1.5 percent of nuclease by weight into the first enzymolysis liquid, adjusting the pH to 4.5-6.0 and the temperature to 45-50 ℃, and reacting for 8-10 h;
adjusting the temperature of the first enzymolysis liquid treated by acid protease and nuclease to 40-55 ℃, adding helicase accounting for 0.5 percent of the weight of the yeast stock solution treated by the acid protease and the papain and pancreatin accounting for 1.0 percent of the weight of the yeast stock solution treated by the acid protease and the papain, adjusting the pH to 6.0-7.5, filling ozone, and stirring the first enzymolysis liquid under the condition of 200-;
(3) and (3) enzymolysis: adjusting the temperature of the second enzymolysis liquid to 20-25 ℃, reducing the temperature to-45 ℃ at the speed of 5 ℃/min, maintaining the temperature for 0.5min after reducing the temperature to-45 ℃, and increasing the temperature of the second enzymolysis liquid to 20-25 ℃ at the speed of 12 ℃/min; after the temperature is raised to 20-25 ℃, adding glutaminase and deaminase which are 0.5 percent and 1.0 percent of the weight of the second enzymolysis liquid into the second enzymolysis liquid, adjusting the pH to 5.5-6.0 and the temperature to 45-50 ℃, and reacting for 3-4 hours;
regulating the temperature of the second enzymatic hydrolysate treated by the glutaminase and the deaminase to 40-55 ℃, adding the snailase accounting for 1 percent of the weight of the second enzymatic hydrolysate treated by the glutaminase and the deaminase and the pancreatin accounting for 1 percent of the weight of the second enzymatic hydrolysate treated by the glutaminase and the deaminase, regulating the pH to 6.5-7.5, filling ozone, and stirring the second enzymatic hydrolysate under the condition of 200-300 revolutions per minute for 2-3 hours to obtain a third enzymatic hydrolysate;
s24, after the enzymolysis is finished, heating the obtained third enzymolysis liquid to 90 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a yeast extract stock solution;
s25, adding activated carbon 3% of the yeast extract stock solution by weight, stirring uniformly, keeping the temperature at 55 ℃ for 60-90min, centrifuging, removing sediments to obtain yeast extract clear solution, and filtering under the pressure of 0.25-0.35 MPa;
s26, filtering the clear yeast extract liquid by a microfiltration ceramic membrane, and controlling the operation temperature to be 55-65 ℃ to obtain microfiltration membrane permeate;
filtering the microfiltration membrane permeate through a roll-type ultrafiltration membrane, and controlling the operation temperature to be 55-65 ℃ to obtain ultrafiltration membrane permeate;
concentrating the ultrafiltration membrane retentate by a roll-type high-pressure reverse osmosis membrane to remove water and partial residual inorganic salt and small molecular impurities, and controlling the operation temperature to be below 40 ℃ to obtain a yeast extract concentrated solution;
s27, drying the yeast extract concentrated solution by a vacuum freeze drying method to obtain the yeast extract.
5. The small molecule polypeptide complex nutrient of claim 4, wherein the active dry yeast cell has a protein content of 40-45%, a carbohydrate content of 8-10%, and a moisture content of 4-5%.
6. The small molecule polypeptide complex nutrient of claim 1, wherein the extraction method of gardenia fruit oil comprises:
s31, putting fresh gardenia fruits into water, soaking at 25 ℃ for 24-36h, taking out, washing with water for 2-3 times, drying, grinding, and sieving with a 100-mesh sieve to obtain gardenia fruit powder;
s32, taking gardenia fruit powder, adding deionized water with the weight 5-10 times of that of the gardenia fruit powder to obtain an enzymolysis raw material, and carrying out enzymolysis on the enzymolysis raw material; wherein, the enzymolysis process comprises the following steps:
carrying out first enzymolysis: adding trypsin in an amount of 5% of the weight of the gardenia fruit powder and adding a permeability regulating solution for regulating the permeability of cell membranes and/or cell walls in an amount of 45-55% of the weight of the gardenia fruit powder into the enzymolysis raw materials, regulating the pH value to 6.5-7.5, fully stirring, heating to 42-45 ℃ while stirring, and preserving heat for 30-45min to obtain a first enzymolysis system; the permeability regulating liquid consists of acid solution, glycerol, sodium chloride and lysozyme, and the acid solution comprises the following components in percentage by weight: glycerol: sodium chloride: lysozyme is 1: (0.7-1.0): (0.02-0.05): (0.03-0.06);
and (3) carrying out second enzymolysis: after the temperature of the first enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 3.5-4.5, adding pectinase according to 4% of the weight of the first system, fully stirring, heating to 50-60 ℃ while stirring, and preserving heat for 30-35min to obtain a second enzymolysis system;
and (3) carrying out third enzymolysis: after the temperature of the second enzymolysis system is reduced to 20-25 ℃, adjusting the pH value to 4.0-5.5, adding cellulase according to 3.5% of the weight of the second enzymolysis system, fully stirring, heating to 50-65 ℃ while stirring, and preserving heat for 25-35min to obtain a third enzymolysis system;
s33, after the enzymolysis process in the step S22 is finished, heating the obtained third enzymolysis system to 85 ℃, and maintaining for 10min to finish the enzyme deactivation process to obtain a gardenia fruit enzymolysis system;
s34, adding activated carbon in an enzymolysis system of the gardenia fruit according to 3% of the weight of the gardenia fruit, uniformly stirring, keeping the temperature at 65 ℃ for 65-85min, centrifuging, and removing sediments to obtain a crude extract of gardenia fruit oil; filtering the crude gardenia fruit oil extract by diatomite to obtain a gardenia fruit oil extract, wherein the filtering pressure is 0.3-0.4 MPa; adding 3% of active carbon into the gardenia fruit oil extracting solution according to the weight, standing for 45-50min, centrifuging, and removing sediments; standing for 2-3h, and collecting the upper oil layer to obtain the fructus Gardeniae fruit oil.
7. A preparation method of a micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity is characterized by comprising the following steps:
s100, weighing the components according to the component dosage in the claim 1, and mixing for 4-6 minutes to obtain a mixture;
s200, feeding the mixture into a granulator for granulation to obtain a coarse finished product, wherein the steam pressure in the granulator is 0.5-0.8Mpa, the granulation temperature is 75-85 ℃, and the diameter of a die hole of the granulator is 1.5-3 mm;
s300, sieving the crude product by using an 8-mesh sieve to finally obtain the micromolecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and the preparation method thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911021187.2A CN110771890A (en) | 2019-10-25 | 2019-10-25 | Small-molecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911021187.2A CN110771890A (en) | 2019-10-25 | 2019-10-25 | Small-molecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110771890A true CN110771890A (en) | 2020-02-11 |
Family
ID=69386459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911021187.2A Pending CN110771890A (en) | 2019-10-25 | 2019-10-25 | Small-molecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110771890A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113502314A (en) * | 2021-07-01 | 2021-10-15 | 上海应用技术大学 | Method for preparing yeast active polypeptide by enzymolysis of compound enzyme method |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103060078A (en) * | 2011-10-20 | 2013-04-24 | 中国科学院兰州化学物理研究所 | Method for aqueous enzymatic extraction of gardenia oil |
CN105077152A (en) * | 2015-07-15 | 2015-11-25 | 珠海天香苑生物科技发展股份有限公司 | Yeast extract and preparation method thereof |
CN107136509A (en) * | 2017-07-06 | 2017-09-08 | 北京爱博优营养科技有限公司 | It is a kind of to be used to improve functional food of immunity and preparation method thereof |
CN109055469A (en) * | 2018-08-29 | 2018-12-21 | 武汉轻工大学 | A kind of preparation method of pumpkin albumen |
CN109730309A (en) * | 2019-01-10 | 2019-05-10 | 蕴彤本草(北京)生物科技有限公司 | Brain tonic and intelligence development tranquilizing the mind relieves stress fructus alpiniae oxyphyllae complex polypeptide nutrition element and preparation method |
CN109880869A (en) * | 2019-02-27 | 2019-06-14 | 江苏经贸职业技术学院 | A kind of pumpkin protolysate and preparation method thereof |
CN110037302A (en) * | 2019-04-10 | 2019-07-23 | 上海琪磊健康管理有限公司 | The formula and preparation process that a kind of relieving mental strain and helping sleep and enteron aisle are adjusted |
-
2019
- 2019-10-25 CN CN201911021187.2A patent/CN110771890A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103060078A (en) * | 2011-10-20 | 2013-04-24 | 中国科学院兰州化学物理研究所 | Method for aqueous enzymatic extraction of gardenia oil |
CN105077152A (en) * | 2015-07-15 | 2015-11-25 | 珠海天香苑生物科技发展股份有限公司 | Yeast extract and preparation method thereof |
CN107136509A (en) * | 2017-07-06 | 2017-09-08 | 北京爱博优营养科技有限公司 | It is a kind of to be used to improve functional food of immunity and preparation method thereof |
CN109055469A (en) * | 2018-08-29 | 2018-12-21 | 武汉轻工大学 | A kind of preparation method of pumpkin albumen |
CN109730309A (en) * | 2019-01-10 | 2019-05-10 | 蕴彤本草(北京)生物科技有限公司 | Brain tonic and intelligence development tranquilizing the mind relieves stress fructus alpiniae oxyphyllae complex polypeptide nutrition element and preparation method |
CN109880869A (en) * | 2019-02-27 | 2019-06-14 | 江苏经贸职业技术学院 | A kind of pumpkin protolysate and preparation method thereof |
CN110037302A (en) * | 2019-04-10 | 2019-07-23 | 上海琪磊健康管理有限公司 | The formula and preparation process that a kind of relieving mental strain and helping sleep and enteron aisle are adjusted |
Non-Patent Citations (1)
Title |
---|
胡斌杰等: "《食品生产工艺》", 30 September 2018 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113502314A (en) * | 2021-07-01 | 2021-10-15 | 上海应用技术大学 | Method for preparing yeast active polypeptide by enzymolysis of compound enzyme method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI516280B (en) | Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging | |
CN108210878A (en) | The cordyceps sinensis Saussurea Polysaccharide compound of kidney-tonifying sperm-generating | |
CN106047974A (en) | Hippocampus polypeptide with antioxidant and anti-fatigue activity and preparation technology thereof | |
CN102296014A (en) | Preparation method for selenium cordyceps wine | |
CN103301321B (en) | Thrombolytic active polysaccharide mixture preparation technology | |
CN110915980A (en) | Sunflower disc peptide powder, and preparation method and application thereof | |
CN110771890A (en) | Small-molecule polypeptide compound nutrient for soothing nerves, helping sleep and improving immunity and preparation method thereof | |
CN108497118B (en) | Alcohol-dispelling health tea and preparation method thereof | |
CN113040386A (en) | Compound preparation for improving immunity and resisting fatigue and preparation method thereof | |
CN112971151A (en) | Ginseng and walnut peptide composition capable of improving immunity and preparation method thereof | |
KR20170116532A (en) | Maca and date palms, Ganoderma lucidum, perform exercises containing fermented antler extract as an active ingredient skills enhancement and promotion fatigue complex composition | |
CN112999247A (en) | Preparation and extraction process of ganoderma lucidum spore powder zymolyte, product and application thereof | |
CN110721305A (en) | Small molecular polypeptide botanical drug for improving immunity and treating insomnia and preparation method thereof | |
CN109589400B (en) | Composition with neuroprotective effect | |
KR101408101B1 (en) | Food for improving liver function comprising black rice culture of Lentinus edodes mycelia adding Hovenia dulcis extract as effective component | |
CN108187032A (en) | Cordyceps sinensis collagen peptide piece | |
CN110607245B (en) | Lucid ganoderma cordyceps sinensis capsule and preparation method thereof | |
CN108546620A (en) | A kind of deer ginseng small-molecular peptides nourish wine and preparation method thereof | |
CN108148715A (en) | Cordyceps sinensis polysaccharide wine | |
CN107937465A (en) | A kind of preparation method of polypeptide and the polypeptide of acquisition | |
CN114098089A (en) | Composite peptide composition and composite peptide seasoning tea | |
US6129919A (en) | Method of producing fermented sword beans | |
EP1398036B1 (en) | Ganoderma lucidum spores for treatment of systemic lupus erytrhomatosus (SLE) | |
CN105087284A (en) | Compound raspberry health wine and preparation method thereof | |
CN110711245A (en) | Active polysaccharide compound botanical drug for improving immunity and resisting fatigue and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200211 |
|
WD01 | Invention patent application deemed withdrawn after publication |